2 innovative scientific platforms

Ipsen is renowned for its expertise in toxins and peptides. The Group operates two technological platforms. Both are centers of excellence in these fields and both have substantial potential for differentiation. We also draw on this expertise to use the synergies generated between toxins and peptides in hybrid molecules to obtain targeted secretion inhibitors (TSIs). With their unique properties, these molecules offer potential in the treatment of neuromuscular, endocrine and proliferative disorders, as well as for pain.

Long-standing expertise in peptides 

 

From research to the formulation of analogs of natural peptides

Ipsen’s initial exploration of the many possibilities offered by peptides dates back to the 1970s. Peptides are compounds made up of dozens of amino acids, and bridge the gap between small chemical molecules and large therapeutic proteins like antibodies. Through the discovery of peptides and their formulation, the Group leverages this expertise for projects focusing on analogs of natural peptides with the potential to satisfy unmet patient needs. These products reflect Ipsen’s ability to combine advancements in research with galenic innovation.

 

Open innovation for new medical applications

The peptide platform capitalizes on its knowledge in this area in an innovative manner to leverage the huge proportion of molecular targets yet to be developed as drugs, such as small molecules and antibodies. Since April 2015, US R&D activities have been located in Cambridge (Massachusetts), one of the leading hubs for life sciences research across the globe. The objective: bring Ipsen closer to several key partners based in the region, including major hospital centers, medical schools, biotech companies and leading universities. The Group has therefore been able to strengthen its leadership in this field. Pharmaceutical development is conducted in Dreux (France).

2

Excellent technological platforms: toxins and peptides

> €200 M

Expenditure in R&D in 2016

Last update 31/08/2016